

## 7 Literaturverzeichnis

1. Vogelstein B, Kinzler KW. The multistep nature of cancer. *Trends Genet* 1993 Apr;9(4):138-41
2. Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. *J Pathol.* 2000 Mar;190(4):412-6. Review.
3. Nowell PC. The clonal evolution of tumor cell populations. *Science* 1976 Oct 1;194(4260):23-8
4. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. *J Cell Biol* 1994 Feb;124(4):619-26
5. Reyher U, Sträter J, Möller P. Interdependenz von Adhäsionsverlust und Apoptose als tragendes Prinzip der Gewebemöostase und deren Störung in der Neoplasie. *Handbuch der Molekularen Medizin, Band 2, Tumorerkrankungen*, Hrsg.: D. Ganten und K. Ruckpaul, Springer (1998). P. 149-159
6. Morgan RA, Anderson WF Human gene therapy. *Annu Rev Biochem* 1993;62:191-217
7. McKusick VA., *Mendelian Inheritance in Man : A Catalog of Human Genes and Genetic Disorders (12th Ed)* Johns Hopkins Univ Press
8. Rosenthal A. Das Humangenomprojekt und seine Bedeutung für die Medizin im 21. Jahrhundert. *Gentechnik-Grenzzone menschlichen Handelns?*, Verlag Versicherungswirtschaft GmbH 1999, Karlsruhe Seite 69-93
9. Gossen M, Bujard H Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc Natl Acad Sci U S A* 1992 Jun 15;89(12):5547-51
10. Pomer S, Thiele R, Staehler G, Drehmer I, Lohrke H, Schirrmacher V. Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization. *Urologe A.* 1995 May;34(3):215-20. German.
11. Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA Clinical effects and toxicity of interleukin-2 in patients with cancer. *Cancer* 1986 Dec 15;58(12):2764-72

12. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. *Ann Surg* 1989 Oct;210(4):474-84; discussion 484-5
13. Schirmmayer V. Tumor vaccines and active specific immunotherapy. *Internist (Berl)* 1997 Nov;38(11):1050-4
14. Oettgen HF et. al.: The history of cancer immunotherapy. In: De Vita V.T. Helman, S., Rosenberg, S.A. (Hrsg. ) *Biologic Therapy of Cancer, principles and practice*. Lippincott, New York, S. 87-119
15. Pezzutto A. Immunotherapy: cytokines and tumor cell vaccines. *Internist (Berl)*. 1998 Nov;39(11):1131-8. Review.
16. Peron JM, Shurin MR and Lotze MT : *Cytokine Gene Therapy of Cancer. Gene Therapy of Cancer*, Editors: Lattime EC, Gerson SL, Academic Press. 1999 Chap.23, p359-371
17. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. *J Exp Med*. 1996 Mar 1;183(3):725-9. Review.
18. Coulie PG. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? *Mol Med Today*. 1997 Jun;3(6):261-8. Review.
19. Matzinger P. Tolerance, danger, and the extended family. *Annu Rev Immunol*. 1994;12:991-1045. Review.
20. Pardoll DM. Cancer vaccines. *Nat Med*. 1998 May;4(5 Suppl):525-31. Review.
21. Trehu EG, Isner JM, Mier JW, Karp DD, Atkins MB. Possible myocardial toxicity associated with interleukin-4 therapy. *J Immunother*. 1993 Nov;14(4):348-51.
22. Elder EM, Lotze MT, Whiteside TL. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. *Hum Gene Ther*. 1996 Mar 1;7(4):479-87.
23. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. *Annu Rev Immunol*. 1995;13:399-415. Review.
24. Wittig B, Märten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kruopis S, Albers A, Löffel J, Albers P, Müller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IGH Therapeutic Vaccination against metastatic carcinoma by expression-modulated and immuno-modified autologous tumor cells: A first clinical phase I/II trial. *Human Gene Therapy*, 2001 Feb 10,12(13):267-78

25. Moller P, Moller H, Sun Y, Dorbic T, Henz BM, Wittig B, Schadendorf D. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells. *Cancer Gene Ther* 2000 Jul;7(7):976-84
26. Gasson JC. Molecular physiology of granulocyte-macrophage colony-stimulating factor. *Blood*. 1991 Mar 15;77(6):1131-45. Review.
27. Burgess AW. in *Peptide Growth Factors and Their Receptors I*, Sporn, MB. and A.B. Roberts, eds. Springer-Verlag 1990, New York, p.190
28. Moore MA. The clinical use of colony stimulating factors. *Annu Rev Immunol*. 1991;9:159-91. Review.
29. Nicola NA. Hemopoietic cell growth factors and their receptors. *Annu Rev Biochem*. 1989;58:45-77. Review.
30. Costello RT. Therapeutic use of granulocyte-macrophage colony-stimulating factor (GM-CSF). A review of recent experience. *Acta Oncol*. 1993;32(4):403-8. Review.
31. Freund M, Kleine HD. The role of GM-CSF in infection. *Infection*. 1992;20 Suppl 2:S84-92. Review.
32. Goodall GJ, Bagley CJ, Vadas MA, Lopez AF. A model for the interaction of the GM-CSF, IL-3 and IL-5 receptors with their ligands. *Growth Factors*. 1993;8(2):87-97. Review.
33. Park LS, Martin U, Sorensen R, Luhr S, Morrissey PJ, Cosman D, Larsen A., Cloning of the low-affinity murine granulocyte-macrophage colony-stimulating factor receptor and reconstitution of a high-affinity receptor complex. *Proc Natl Acad Sci U S A*. 1992 May 15;89(10):4295-9.
34. Lopez AF, Elliott MJ, Woodcock J, Vadas MA. GM-CSF, IL-3 and IL-5: cross-competition on human haemopoietic cells. *Immunol Today*. 1992 Dec;13(12):495-500. Review.
35. Gearing DP, King JA, Gough NM, Nicola NA., Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. *EMBO J*. 1989 Dec 1;8(12):3667-76.
36. Ashworth A, Kraft A., Cloning of a potentially soluble receptor for human GM-CSF. *Nucleic Acids Res*. 1990 Dec 11;18(23):7178.
37. Crosier KE, Wong GG, Mathey-Prevot B, Nathan DG, Sieff CA., A functional isoform of the human granulocyte/macrophage colony-stimulating factor

- receptor has an unusual cytoplasmic domain. *Proc Natl Acad Sci U S A*. 1991 Sep 1;88(17):7744-8.
38. Reid, C. et al. (1993) *Dendritic cells in fundamental and clinical immunology*, Kamperdijk et al., eds., Plenum Press, New York, p.257ff
  39. Scheicher, C. et. al. (1993) *Dendritic cells in fundamental and clinical immunology*, Kamperdijk et al., eds., Plenum Press, New York, p.269ff
  40. Lopez AF, Eglinton JM, Lyons AB, Tapley PM, To LB, Park LS, Clark SC, Vadas MA. Human interleukin-3 inhibits the binding of granulocyte-macrophage colony-stimulating factor and interleukin-5 to basophils and strongly enhances their functional activity. *J Cell Physiol*. 1990 Oct;145(1):69-77.
  41. Bussolino F, Wang JM, Defilippi P, Turrini F, Sanavio F, Edgell CJ, Aglietta M, Arese P, Mantovani A. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. *Nature*. 1989 Feb 2;337(6206):471-3.
  42. Sawyers CL, Golde DW, Quan S, Nimer SD. Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia. *Cancer*. 1992 Mar 15;69(6):1342-6.
  43. Omori F, Okamura S, Shimoda K, Otsuka T, Harada M, Niho Y. Levels of human serum granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor under pathological conditions. *Biotherapy*. 1992;4(2):147-53.
  44. Nakamura Y, Ozaki T, Kamei T, Kawaji K, Banno K, Miki S, Fujisawa K, Yasuoka S, Ogura T. Increased granulocyte/macrophage colony-stimulating factor production by mononuclear cells from peripheral blood of patients with bronchial asthma. *Am Rev Respir Dis*. 1993 Jan;147(1):87-91.
  45. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. *Proc Natl Acad Sci U S A*. 1993 Apr 15;90(8):3539-43.
  46. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Cliff S, Dranoff G, et al., Vaccination with irradiated autologous

- melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. *Proc Natl Acad Sci U S A*. 1998 Oct 27;95(22):13141-6.
47. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JL, Bierer BE, Croop JM. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. *Blood*. 1998 Jan 1;91(1):222-30.
  48. Namen AE, Lupton S, Hjerrild K, Wignall J, Mochizuki DY, Schmierer A, Mosley B, March CJ, Urdal D, Gillis S. Stimulation of B-cell progenitors by cloned murine interleukin-7. *Nature*. 1988 Jun 9;333(6173):571-3.
  49. Goodwin RG, Lupton S, Schmierer A, Hjerrild KJ, Jerzy R, Clevenger W, Gillis S, Cosman D, Namen AE. Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells. *Proc Natl Acad Sci U S A*. 1989 Jan;86(1):302-6.
  50. Goodwin RG, Namen AE. The cloning and characterization of interleukin7. *Year Immunol*. 1989-90;6:127-39. Review.
  51. Lupton SD, Gimpel S, Jerzy R, Brunton LL, Hjerrild KA, Cosman D, Goodwin RG. Characterization of the human and murine IL-7 genes. *J Immunol*. 1990 May 1;144(9):3592-601.
  52. Henney CS. Interleukin 7: effects on early events in lymphopoiesis. *Immunol Today*. 1989 May;10(5):170-3. Review.
  53. Moller P, Czarnetzki BM, Schadendorf D. Interleukin 7 in dermatology. Molecular, immunologic and preclinical aspects. *Hautarzt*. 1995 Oct;46(10):676-82. Review. German.
  54. Herr W, Wolfel T, Heike M, Meyer zum Buschenfelde KH, Knuth A. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. *Cancer Immunol Immunother*. 1994 Aug;39(2):93-9.
  55. Komschlies KL, Gregorio TA, Gruys ME, Back TC, Faltynek CR, Wiltrot RH. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. *J Immunol*. 1994 Jun 15;152(12):5776-84.

56. Goodwin RG, Friend D, Ziegler SF, Jerzy R, Falk BA, Gimpel S, Cosman D, Dower SK, March CJ, Namen AE, et al., Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. *Cell*. 1990 Mar 23;60(6):941-51.
57. Noguchi M, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X, Leonard WJ. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. *Science*. 1993 Dec 17;262(5141):1877-80.
58. Appasamy PM. Interleukin-7 and lymphopoiesis: biological and clinical implications. *Cancer Treat Res*. 1995;80:235-60.
59. Page TH, Willcocks JL, Taylor-Fishwick DA, Foxwell BM. Characterization of a novel high affinity human IL-7 receptor. Expression on T cells and association with IL-7 driven proliferation. *J Immunol*. 1993 Nov 1;151(9):4753-63.
60. Uckun FM, Tuel-Ahlgren L, Obuz V, Smith R, Dibirdik I, Hanson M, Langlie MC, Ledbetter JA. Interleukin 7 receptor engagement stimulates tyrosine phosphorylation, inositol phospholipid turnover, proliferation, and selective differentiation to the CD4 lineage by human fetal thymocytes. *Proc Natl Acad Sci U S A*. 1991 Jul 15;88(14):6323-7.
61. Costello R, Imbert J, Olive D. Interleukin-7, a major T-lymphocyte cytokine. *Eur Cytokine Netw*. 1993 Jul-Aug;4(4):253-62. Review.
62. Namen AE, Schmierer AE, March CJ, Overell RW, Park LS, Urdal DL, Mochizuki DY., OMIM B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. *J Exp Med*. 1988 Mar 1;167(3):988-1002.
63. Morrissey PJ, Conlon P, Charrier K, Braddy S, Alpert A, Williams D, Namen AE, Mochizuki D. Administration of IL-7 to normal mice stimulates B-lymphopoiesis and peripheral lymphadenopathy. *J Immunol*. 1991 Jul 15;147(2):561-8.
64. Takeda S, Gillis S, Palacios R. In vitro effects of recombinant interleukin 7 on growth and differentiation of bone marrow pro-B- and pro-T-lymphocyte clones and fetal thymocyte clones. *Proc Natl Acad Sci U S A*. 1989 Mar;86(5):1634-8.
65. Muegge K, Vila MP, Durum SK. Interleukin-7: a cofactor for V(D)J rearrangement of the T cell receptor beta gene. *Science*. 1993 Jul 2;261(5117):93-5.

66. Bertagnolli M, Herrmann S. IL-7 supports the generation of cytotoxic T lymphocytes from thymocytes. Multiple lymphokines required for proliferation and cytotoxicity. *J Immunol.* 1990 Sep 15;145(6):1706-12.
67. Morrissey PJ, Goodwin RG, Nordan RP, Anderson D, Grabstein KH, Cosman D, Sims J, Lupton S, Acres B, Reed SG. Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. *J Exp Med.* 1989 Mar 1;169(3):707-16.
68. Armitage RJ, Namen AE, Sassenfeld HM, Grabstein KH. Regulation of human T cell proliferation by IL-7. *J Immunol.* 1990 Feb 1;144(3):938-41.
69. Chazen GD, Pereira GM, LeGros G, Gillis S, Shevach EM. Interleukin 7 is a T-cell growth factor. *Proc Natl Acad Sci U S A.* 1989 Aug;86(15):5923-7.
70. Grabstein KH, Namen AE, Shanebeck K, Voice RF, Reed SG, Widmer MB. Regulation of T cell proliferation by IL-7. *J Immunol.* 1990 Apr 15;144(8):3015-20.
71. Costello R, Imbert J, Olive D. Interleukin-7, a major T-lymphocyte cytokine. *Eur Cytokine Netw.* 1993 Jul-Aug;4(4):253-62. Review.
72. Alderson MR, Sassenfeld HM, Widmer MB. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. *J Exp Med.* 1990 Aug 1;172(2):577-87.
73. Hickman CJ, Crim JA, Mostowski HS, Siegel JP. Regulation of human cytotoxic T lymphocyte development by IL-7. *J Immunol.* 1990 Oct 15;145(8):2415-20.
74. Jicha DL, Schwarz S, Mule JJ, Rosenberg SA. Interleukin-7 mediates the generation and expansion of murine allosensitized and antitumor CTL. *Cell Immunol.* 1992 Apr 15;141(1):71-83.
75. Murphy WJ, Back TC, Conlon KC, Komschlies KL, Ortaldo JR, Sayers TJ, Wiltrout RH, Longo DL. Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. *J Clin Invest.* 1993 Oct;92(4):1918-24.
76. Sica D, Rayman P, Stanley J, Edinger M, Tubbs RR, Klein E, Bukowski R, Finke JH. Interleukin 7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal-cell carcinoma. *Int J Cancer.* 1993 Apr 1;53(6):941-7.

77. Wiltrout RH, Gregorio TA, Fenton RG, Longo DL, Ghosh P, Murphy WJ, Komschlies KL. Cellular and molecular studies in the treatment of murine renal cancer. *Semin Oncol.* 1995 Feb;22(1):9-16. Review.
78. Alderson MR, Tough TW, Ziegler SF, Grabstein KH. Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. *J Exp Med.* 1991 Apr 1;173(4):923-30.
79. Bohm M, Moller P, Kalbfleisch U, Worm M, Czarnetzki BM, Schadendorf D. Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells. *Br J Cancer.* 1994 Jul;70(1):54-9.
80. Lynch DH, Miller RE. Induction of murine lymphokine-activated killer cells by recombinant IL-7. *J Immunol.* 1990 Sep 15;145(6):1983-90.
81. Ditunno P, Tso CL, Sakata T, deKernion JB, Belldegrun A. Regulatory effects of interleukin-7 on renal tumor infiltrating lymphocytes. *Urol Res.* 1992;20(3):205-10.
82. Lotze MT, Zeh HJ 3d, Elder EM, Cai Q, Pippin BA, Rosenstein MM, Whiteside TL, Herberman R. Use of T-cell growth factors (interleukins 2, 4, 7, 10, and 12) in the evaluation of T-cell reactivity to melanoma. *J Immunother.* 1992 Oct;12(3):212-7.
83. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. *Proc Natl Acad Sci U S A.* 1993 Apr 1;90(7):2774-8.
84. McBride WH, Thacker JD, Comora S, Economou JS, Kelley D, Hogge D, Dubinett SM, Dougherty GJ. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. *Cancer Res.* 1992 Jul 15;52(14):3931-7.
85. Fricker J. Interleukin 7 on trial for melanoma treatment. *Mol Med Today.* 1996 Jan;2(1):2.
86. Aoki T, Tashiro K, Miyatake S, Kinashi T, Nakano T, Oda Y, Kikuchi H, Honjo T. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. *Proc Natl Acad Sci U S A.* 1992 May 1;89(9):3850-4.
87. Schmidt-Wolf IG, Huhn D, Neubauer A, Wittig B. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. *Hum Gene Ther.* 1994 Sep;5(9):1161-8.

88. Schadendorf D, Czarnetzki BM, Wittig B. Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma. *J Mol Med.* 1995 Sep;73(9):473-7.
89. Moller P, Sun Y, Dorbic T, Alijagic S, Makki A, Jurgovsky K, Schroff M, Henz BM, Wittig B, Schadendorf D. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. *Br J Cancer.* 1998 Jun;77(11):1907-16.
90. Felgner PL, Barenholz Y, Behr JP, Cheng SH, Cullis P, Huang L, Jessee JA, Seymour L, Szoka F, Thierry AR, Wagner E, Wu G. Nomenclature for synthetic gene delivery systems. *Hum Gene Ther.* 1997 Mar 20;8(5):511-2.
91. Caplen NJ, Kinrade E, Sorgi F, Gao X, Gruenert D, Geddes D, Coutelle C, Huang L, Alton EW, Williamson R. In vitro liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE. *Gene Ther.* 1995 Nov;2(9):603-13.
92. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. *Proc Natl Acad Sci U S A.* 1987 Nov;84(21):7413-7.
93. Legendre JY, Szoka FC Jr. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. *Pharm Res.* 1992 Oct;9(10):1235-42.
94. Matsui H, Johnson LG, Randell SH, Boucher RC. Loss of binding and entry of liposome-DNA complexes decreases transfection efficiency in differentiated airway epithelial cells. *J Biol Chem.* 1997 Jan 10;272(2):1117-26.
95. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ. Cellular and molecular barriers to gene transfer by a cationic lipid. *J Biol Chem.* 1995 Aug 11;270(32):18997-9007.
96. Caplen, Lipid gene Transfer, a story of Simplicity and Complexity. (1998) *Gene Therapy NATO ASI Series, Cell Biology, Vol H 105, p.185, Hrsg. Xanthopoulos, K.G., Springer*
97. Marcel T, Grausz JD. The TMC Worldwide Gene Therapy Enrollment Report, end 1996. *Hum Gene Ther.* 1997 Apr 10;8(6):775-800.
98. Graham FL, Eb AJ van der. A new technique for the assay of infectivity of human adenovirus 5 DNA. *Virology.* 1973 Apr;52(2):456-67.

99. Ishikawa Y, Homcy CJ. High efficiency gene transfer into mammalian cells by a double transfection protocol. *Nucleic Acids Res.* 1992 Aug 25;20(16):4367.
100. Ledley FD. Nonviral gene therapy: the promise of genes as pharmaceutical products. *Hum Gene Ther.* 1995 Sep;6(9):1129-44. Review.
101. Uherek, C. et. al.: Modular Fusion Proteins for Receptor-mediated Gene Delivery. (1998) *Gene Therapy NATO ASI Series, Cell Biology, Vol H 105*, p.185, Hrsg Xanthopoulos, K.G., Springer
102. Hanania EG, Kavanagh J, Hortobagyi G, Giles RE, Champlin R, Deisseroth AB. Recent advances in the application of gene therapy to human disease. *Am J Med.* 1995 Nov;99(5):537-52. Review.
103. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. *Semin Oncol.* 1996 Feb;23(1):101-7. Review.
104. Smith JG, Walzem RL, German JB. Liposomes as agents of DNA transfer. *Biochim Biophys Acta.* 1993 Dec 21;1154(3-4):327-40.
105. Zhou X, Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. *Biochim Biophys Acta.* 1994 Jan 19;1189(2):195-203.
106. Wrobel I, Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. *Biochim Biophys Acta.* 1995 May 4;1235(2):296-304.
107. Zimmermann U, Schulz J, Pilwat G. Transcellular ion flow in *Escherichia coli* B and electrical sizing of bacterias. *Biophys J.* 1973 Oct;13(10):1005-13.
108. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. *EMBO J.* 1982;1(7):841-5.
109. Fromm M, Taylor LP, Walbot V. Expression of genes transferred into monocot and dicot plant cells by electroporation. *Proc Natl Acad Sci U S A.* 1985 Sep;82(17):5824-8.
110. Grey M, Brendel M. A ten-minute protocol for transforming *Saccharomyces cerevisiae* by electroporation. *Curr Genet.* 1992 Oct;22(4):335-6.
111. Delorme E. Transformation of *Saccharomyces cerevisiae* by electroporation. *Appl Environ Microbiol.* 1989 Sep;55(9):2242-6.
112. Calvin NM, Hanawalt PC. High-efficiency transformation of bacterial cells by electroporation. *J Bacteriol.* 1988 Jun;170(6):2796-801.

113. Van Tendeloo VF, Snoeck HW, Lardon F, Vanham GL, Nijs G, Lenjou M, Hendriks L, Van Broeckhoven C, Moulijn A, Rodrigus I, Verdonk P, Van Bockstaele DR, Berneman ZN. Nonviral transfection of distinct types of human dendritic cells: high-efficiency gene transfer by electroporation into hematopoietic progenitor- but not monocyte-derived dendritic cells. *Gene Ther.* 1998 May;5(5):700-7.
114. Wadsworth P. Microinjection of mitotic cells. *Methods Cell Biol.* 1999;61:219-31. Review.
115. Hammer RE, Pursel VG, Rexroad CE Jr, Wall RJ, Bolt DJ, Ebert KM, Palmiter RD, Brinster RL. Production of transgenic rabbits, sheep and pigs by microinjection. *Nature.* 1985 Jun 20-26;315(6021):680-3.
116. Kleuss C, Scherubl H, Hescheler J, Schultz G, Wittig B. Different beta-subunits determine G-protein interaction with transmembrane receptors. *Nature.* 1992 Jul 30;358(6385):424-6.
117. Kleuss C, Schultz G, Wittig B. Microinjection of antisense oligonucleotides to assess G-protein subunit function. *Methods Enzymol.* 1994;237:345-55.
118. Kaiser A, Wolf-Breitinger M, Albers A, Dorbic T, Wittig B, Riecken EO, Rosewicz S. Retinoic acid receptor gamma1 expression determines retinoid sensitivity in pancreatic carcinoma cells. *Gastroenterology.* 1998 Oct;115(4):967-77.
119. Yang NS. Gene transfer into mammalian somatic cells in vivo. *Crit Rev Biotechnol.* 1992;12(4):335-56. Review.
120. Lo DC, McAllister AK, Katz LC. Neuronal transfection in brain slices using particle-mediated gene transfer. *Neuron.* 1994 Dec;13(6):1263-8.
121. Tüting, T. and Albers A. Particle-mediated Gene Transfer into Dendritic Cells: A Novel Strategy for the Induction of Immune Responses against Tumor Antigens, *Gene Therapy of Cancer*. Editors: Walther, W., Stein, U. 2/2000 Humana Press
122. Moller P, Sun Y, Dorbic T, Alijagic S, Makki A, Jurgovsky K, Schroff M, Henz BM, Wittig B, Schadendorf D. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. *Br J Cancer.* 1998 Jun;77(11):1907-16.
123. Sun Y, Jurgovsky K, Moller P, Alijagic S, Dorbic T, Georgieva J, Wittig B, Schadendorf D. Vaccination with IL-12 gene-modified autologous melanoma

- cells: preclinical results and a first clinical phase I study. *Gene Ther.* 1998 Apr;5(4):481-90.
124. Sanford JC, Smith FD, Russell JA. Optimizing the biolistic process for different biological applications. *Methods Enzymol.* 1993;217:483-509.
125. <http://www.atcc.org/>
126. Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acids Res.* 1979 Nov 24;7(6):1513-23
127. Afar B, Merrill J, Clark EA. Detection of lymphocyte subsets using three-color/single-laser flow cytometry and the fluorescent dye peridinin chlorophyll-alpha J *Clin Immunol.* 1991 Sep;11(5):254-61
128. Burkholder JK, Decker J, Yang NS. Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer. *J Immunol Methods.* 1993 Oct 15;165(2):149-56.
129. Bronstein IN, Semendjajew KA., Teubner BG. Taschenbuch der Mathematik, Verlagsgesellschaft, 25. Auflage 1991,
130. Hales TC. Academic Press, Spektrum der Wissenschaft 10/1999 Seite 24
131. Hales TC. „The Honeycomb conjecture“ (1999) Mathematische Beweisführung zum optimalen Verhältnis zwischen Oberfläche und Inhalt. Veröffentlicht im Internet unter <http://xxx.lanl.gov/abs/math.MG/9906042>
132. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. Green fluorescent protein as a marker for gene expression. *Science* 1994 11;263(5148):802-2
133. Cormack BP, Valdivia RH, Falkow S. FACS-optimized mutants of the green fluorescent protein (GFP). *Gene* 1996;173(1 Spec No):33-8
134. Sack F. Charakterisierung und Optimierung der Transfektion von Zelllinien. Diplomarbeit. Angefertigt bei der Mologen AG, Berlin in Kooperation mit der Abteilung Molekularbiologie und BioInformatik am Institut für Molekularbiologie und Biochemie der Freien Universität Berlin